- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04984291
Zimmer Biomet Shoulder Arthroplasty PMCF
Zimmer Biomet Shoulder Arthroplasty Long-term Post Market Clinical Follow-up Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The primary endpoint is defined as survival of the implant at 10 years, which is based on removal or intended removal of at least 1-study implant component and will be determined by using the Kaplan Meier method. The safety of the system will be assessed by monitoring the frequency and incidence of adverse events. Separate analysis will be done for each arm of the study.
The secondary endpoint is represented by the performance and clinical benefits of Zimmer Biomet Shoulder Arthroplasty Systems and its instrumentation after 2 years, which will be assessed by the American Shoulder and Elbow Surgeons (ASES) shoulder score. The secondary endpoint evaluation will also assess the overall pain, functional performance, quality of life and radiographic parameters of all enrolled study subjects.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Ryan Boylan, MBA
- Email: ryan.boylan@zimmerbiomet.com
Study Contact Backup
- Name: Cayla Lafollette, BS
- Phone Number: 574 268-8610
- Email: Cayla.lafollette@zimmerbiomet.com
Study Locations
-
-
-
Fukui, Japan, 910-3113
- Active, not recruiting
- Fukui General Hospital
-
Fukushima, Japan, 973-8555
- Active, not recruiting
- Iwaki City Medical Center
-
Okinawa, Japan, 901-0224
- Active, not recruiting
- Yuuai Medical Center
-
Tokyo, Japan, 180-0003
- Withdrawn
- Kichijoji Minami Hospital
-
-
-
-
-
Whangarei, New Zealand, 0112
- Withdrawn
- Kensington Private Hospital
-
-
-
-
California
-
Irvine, California, United States, 92618
- Active, not recruiting
- Hoag Orthopedic Institute
-
-
Colorado
-
Golden, Colorado, United States, 80401
- Recruiting
- Panorama Orthopaedic and Spine Center
-
Contact:
-
Principal Investigator:
- David Schneider, MD
-
Sub-Investigator:
- James Johnson, MD
-
Contact:
- Paul Lee, PA
- Phone Number: 720-497-6697
- Email: ResearchCoordinators@panoramaortho.com
-
-
Illinois
-
Chicago, Illinois, United States, 60208
- Active, not recruiting
- Northwestern University
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- Terminated
- Norton Healthcare, Inc
-
-
Michigan
-
Royal Oak, Michigan, United States, 48073
- Active, not recruiting
- William Beaumont Hospital
-
-
Minnesota
-
Bloomington, Minnesota, United States, 55431
- Active, not recruiting
- TRIA Orthopaedic Center Research Institute
-
-
Mississippi
-
Jackson, Mississippi, United States, 39202
- Active, not recruiting
- Mississippi Sports Medicine and Orthopaedic Center, PLLC
-
-
Missouri
-
City of Saint Peters, Missouri, United States, 63376
- Active, not recruiting
- Advance Bone and Joint
-
St Louis, Missouri, United States, 63130
- Active, not recruiting
- Washington University
-
-
New York
-
Buffalo, New York, United States, 14215
- Active, not recruiting
- University of Buffalo
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Active, not recruiting
- Rothman Institute
-
-
Utah
-
Murray, Utah, United States, 84107
- Recruiting
- Intermountain Health
-
Principal Investigator:
- Aaron Chamberlain, MD
-
Contact:
- Maha Maleki, BS
- Phone Number: 801-507-8095
- Email: Maha.Maleki@imail.org
-
Contact:
- Matt Schneider, MS
- Phone Number: 801-507-8095
- Email: Matthew.Schneider@imail.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patient must be 20 years of age or older.
- Patient must be anatomically and structurally suited to receive shoulder arthroplasty implants.
Patient is a candidate for shoulder arthroplasty due to one or more of the following:
- Non-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis.
- Rheumatoid arthritis.
- Correction of functional deformity.
- Fractures of the proximal humerus, where other methods of treatment are deemed inadequate.
- Difficult clinical management problems, where other methods of treatment may not be suitable or may be inadequate.
- Patient must be able and willing to complete the protocol required follow-up.
- Patient must be able and willing to sign the IRB/EC approved informed consent.
Patient has grossly deficient rotator, (for reverse application)
- With severe arthropathy and/or
- Previously failed shoulder joint replacement
- Patient must have functional deltoid muscle (for reverse application)
Exclusion Criteria:
- Patient is unwilling or unable to give consent or to comply with the follow-up program.
- Patient has any condition which would in the judgement of the Investigator, place the patient at undue risk or interfere with the study.
- Patient is known to be pregnant or breastfeeding.
- Patient is a vulnerable subject (prisoner, mentally incompetent or unable to understand what participation to the study entails, a known alcohol or drug abuser, and/or anticipated to be non-compliant).
- Patient is uncooperative or patient with neurologic disorders who is incapable or unwilling to follow directions.
- Patient has any sign of infection affecting the shoulder joint or in its proximity which may spread to the implant site.
- Patient has rapid joint destruction, marked bone loss, or bone resorption apparent on roentgenogram.
- Patient has any neuromuscular disease compromising the affected limb that would render the procedure unjustifiable.
- Patient presents with osteoporosis, which in the opinion of the Investigator, may limit the subject's ability to support total shoulder arthroplasty using the study device.
- Patient has osteomalacia.
- Patient has a metabolic disorder that may impair bone formation.
- Patient has deficient rotator cuff.
- Patient presents with significant injury to the upper brachial plexus.
- Patient has paralysis of the axillary nerve.
- Patient has non-functional deltoid or external rotator muscles.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Zimmer Biomet Total Shoulder Arthroplasty System
Patients who are having primary or revision total shoulder arthroplasty who will receive a Zimmer Biomet Total Shoulder Arthroplasty System.
|
Alliance Glenoid used in Primary or Revision Total Shoulder Arthroplasty
Other Names:
Identity Shoulder System is intended to be used in anatomic total shoulder arthroplasty, shoulder hemi-arthroplasty, or total reverse shoulder arthroplasty in both Primary or Revision Total Shoulder Arthroplasty
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Implant Survivorship at 10 years follow-up (Kaplan Meier)
Time Frame: 10 years
|
Based on removal or intended removal of the device and determined using the Kaplan-Meier method.
|
10 years
|
|
Frequency and Incidence of Adverse Events (Safety)
Time Frame: 10 years
|
Monitoring the frequency and incidence of adverse events, serious adverse events, adverse device effects, serious adverse device effects, and unanticipated serious adverse device effects as well as device deficiencies.
|
10 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical efficacy of the device is assessed using the American Shoulder and Elbow Surgeons (ASES) Shoulder Score at 2 years follow-up
Time Frame: 2 years
|
Pain, function, and activities of daily living are measured.
The ASES scale is 0-100.
100 is the highest score and indicates the greatest function while 0 is the lowest score.
|
2 years
|
|
Euroqol Patient Quality of life measured at 2 years follow-up (EQ-5D-5L)
Time Frame: 2 years
|
The EuroQol five dimensions questionnaire (EQ-5D-5L) is a five dimensional self-assessment that is comprised of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
These five dimensions can be used to index a subject's health utility on a scale of 0 to 1, where 0 is death and 1 is perfect health.
The scoring rule for EQ-5D permits scores less than 0, implying that some health states may be worse than death.
|
2 years
|
|
Radiographic Performance [Radiolucency] at 2 years follow-up
Time Frame: 2 years
|
X-rays will be evaluated for radiolucency lines to show the number of subjects with radiolucency.
Radiolucency refers to structures that are less dense and permit the x-ray beam to pass through them.
Radiolucent structures appear dark or black in the radiographic image.
|
2 years
|
|
Radiographic Performance [Osteolysis] at 2 years follow-up
Time Frame: 2 years
|
X-rays will be evaluated for osteolysis to show the number of subjects with osteolysis.
Osteolysis is a progressive condition where bone tissue is destroyed.
In this process, bones lose minerals (mostly calcium), softens, degenerates and become weaker.
|
2 years
|
|
Radiographic Performance [Heterotopic Ossification] at 2 years follow-up
Time Frame: 2 years
|
X-rays will be evaluated for heterotopic ossification to show the number of subjects with heterotopic ossification.
Heterotopic ossification refers to the presence of bone in soft tissue where bone normally does not exist (extraskeletal bone).
|
2 years
|
|
Radiographic Performance [Humeral Component Subsidence] at 2 years follow-up
Time Frame: 2 year
|
X-rays will be evaluated for humeral component subsidence to show the number of subjects with subsidence.
Component Subsidence refers to the presence of the device component gradually sinking or caving into the bone structure.
|
2 year
|
|
Radiographic Performance [Glenoid Component Migration] at 2 years follow-up
Time Frame: 2 year
|
X-rays will be evaluated for glenoid component migration to show the number of subjects with migration.
Component migration refers to the presence of the device component gradually moving anteriorly, posteriorly, superiorly, or inferiorly in relation to original placement.
|
2 year
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Ryan Boylan, Zimmer Biomet
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CMU2019-35E
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.